Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIYAIRI 588 for Intestinal Function After Rectal Cancer Surgery
NCT05759741Phase 1Unknown
- Sponsor
- Huashan Hospital
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of clostridium butyricum in functional gastrointestinal disorder (FGID) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Wexner incontinence score at 1 year. Status: unknown.
02
Drugs
clostridium butyricum
03
Conditions
functional gastrointestinal disorder (FGID)
Beyond the preview
Go deeper on NCT05759741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759741.